Cyclophosphamide, methotrexate, and fluorouracil: still the gold standard?
- PMID: 8683226
- DOI: 10.1200/JCO.1996.14.7.1971
Cyclophosphamide, methotrexate, and fluorouracil: still the gold standard?
Comment on
-
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.J Clin Oncol. 1996 Jul;14(7):1982-92. doi: 10.1200/JCO.1996.14.7.1982. J Clin Oncol. 1996. PMID: 8683228 Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
